Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Z Drago

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|June 10, 2021
Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks ProblemJoshua Z Drago, Komal Jhaveri
Breast Cancer Research : BCR|August 12, 2021
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directionsEmanuela Ferraro, Joshua Z Drago, Shanu Modi
Cancer Discovery|March 3, 2019
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast CancerJoshua Z Drago, Sarat Chandarlapaty, Komal Jhaveri
Nature Reviews. Clinical Oncology|February 9, 2021
Unlocking the potential of antibody-drug conjugates for cancer therapyJoshua Z Drago, Shanu Modi, Sarat Chandarlapaty
Cancer Discovery|April 3, 2023
ADCs or: How I Learned to Stop Worrying and Love ChemotherapyAvantika Gupta, Joshua Z Drago, Sarat Chandarlapaty
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Cancer Treatment Reviews|July 23, 2022
Beyond HER2: Targeting the ErbB receptor family in breast cancerJoshua Z Drago, Emanuela Ferraro, Nour Abuhadra, et al.
Breast Cancer Research and Treatment|November 27, 2025
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancerSophia Zelizer, Grace B Gallagher, Mithat Gonen, et al.
Journal of the National Cancer Institute|August 29, 2020
Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate CancerJoshua Z Drago, Mithat Gönen, Gita Thanarajasingam, et al.
NPJ Breast Cancer|October 22, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysisNelson S Moss, Jolene M Singh, Anne S Reiner, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|June 10, 2021
Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks ProblemJoshua Z Drago, Komal Jhaveri
Breast Cancer Research : BCR|August 12, 2021
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directionsEmanuela Ferraro, Joshua Z Drago, Shanu Modi
Cancer Discovery|March 3, 2019
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast CancerJoshua Z Drago, Sarat Chandarlapaty, Komal Jhaveri
Nature Reviews. Clinical Oncology|February 9, 2021
Unlocking the potential of antibody-drug conjugates for cancer therapyJoshua Z Drago, Shanu Modi, Sarat Chandarlapaty
Cancer Discovery|April 3, 2023
ADCs or: How I Learned to Stop Worrying and Love ChemotherapyAvantika Gupta, Joshua Z Drago, Sarat Chandarlapaty
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Cancer Treatment Reviews|July 23, 2022
Beyond HER2: Targeting the ErbB receptor family in breast cancerJoshua Z Drago, Emanuela Ferraro, Nour Abuhadra, et al.
Breast Cancer Research and Treatment|November 27, 2025
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancerSophia Zelizer, Grace B Gallagher, Mithat Gonen, et al.
Journal of the National Cancer Institute|August 29, 2020
Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate CancerJoshua Z Drago, Mithat Gönen, Gita Thanarajasingam, et al.
NPJ Breast Cancer|October 22, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysisNelson S Moss, Jolene M Singh, Anne S Reiner, et al.
Pageof 3